Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Stage II

Currently, there is 1 ongoing clinical trial investigating new diagnostic approaches for adenosquamous cell lung cancer stage II. This trial focuses on improving early and accurate detection of lung cancer through innovative breath-based testing methods.

Clinical trial locations

• Czechia
  • Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
• Hungary
  • Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings

Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings

This clinical trial is investigating a new diagnostic test called OWL-EVO1 Breath Biopsy test, which aims to help doctors identify lung cancer more accurately in patients who are undergoing screening or have suspicious findings on CT scans.

Main inclusion criteria:

• Adults between 45 and 85 years of age
• Ability to understand the study and provide informed consent
• Body Mass Index (BMI) between 16 and less than 40
• Recent CT scan of the chest area performed within the last 6 months

Main exclusion criteria:

• Individuals who do not meet standard criteria for lung cancer screening using low dose CT scans
• Individuals without suspicious findings on CT scans that might suggest lung cancer
• Individuals whose symptoms or clinical presentation do not suggest lung cancer as a possible diagnosis

Focus and goal of the trial:

The main purpose of this study is to assess how accurately the OWL-EVO1 test can identify lung cancer in people undergoing screening or those who have CT scan findings that might indicate cancer. The test works by analyzing breath samples to detect specific markers that may indicate the presence of lung cancer. This non-invasive approach could potentially lead to earlier and more accurate detection of the disease. The study also evaluates the safety and tolerability of the test to ensure it is safe for participants.

During the study, participants receive an intravenous infusion of a special solution called D5-ethyl-beta-D-glucuronide, which helps in the testing process. Breath samples are then collected at various timepoints to evaluate how well the test can differentiate between individuals with lung cancer and those without it. Participants are monitored throughout the study for any adverse effects related to the test administration.

Investigational diagnostic test:

The study uses OWL-EVO1, a diagnostic breath biopsy test that analyzes volatile organic compounds in the breath. These compounds can indicate the presence of cancer. The test is designed to be non-invasive and aims to improve diagnostic accuracy for lung cancer in individuals with suspicious CT findings or those eligible for screening.

Summary

Currently, only one clinical trial is actively recruiting patients with adenosquamous cell lung cancer stage II. This trial is being conducted in two European countries: Czechia and Hungary. The focus is specifically on improving diagnostic accuracy through innovative breath-based testing rather than testing new cancer treatments. The OWL-EVO1 breath biopsy test represents a novel, non-invasive approach to cancer detection that could complement existing diagnostic methods like CT scanning. The trial’s completion is estimated for late 2024, and results may provide valuable information about the potential of breath-based diagnostics in lung cancer detection.